General Information of Drug (ID: DMEFQND)

Drug Name
Maleimides derivative 3 Drug Info
Synonyms PMID27828716-Compound-SB415286
Cross-matching ID
TTD Drug ID
DMEFQND

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [2]
LY2090314 DMTBFE4 Acute myeloid leukaemia 2A60 Phase 2 [1]
Lithium DMZ3OU6 Bipolar disorder 6A60 Phase 2 [3]
KENPAULLONE DMAGVXW Discovery agent N.A. Patented [1]
CHIR-99021 DMB8MNU Allergic inflammation 4A80-4A85 Patented [1]
TDZD-8 DMG6Q45 Malignant glioma 2A00.0 Patented [1]
AR-A014418 DMUPN01 Ovarian cancer 2C73 Patented [1]
PMID27828716-Compound-21 DMO1NAR N. A. N. A. Patented [1]
Thiadiazolidindione derivative 2 DM5AUL0 N. A. N. A. Patented [1]
PMID27828716-Compound-18 DMNR6KL N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glycogen synthase kinase-3 alpha (GSK-3A) TTRZQE3 GSK3A_HUMAN Inhibitor [1]

References

1 Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
2 Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia. Expert Opin Ther Targets. 2008 Nov;12(11):1367-76.
3 The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of -catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874.